HiveProspectStranded Biotech Asset IntelligenceResearch intelligence
Research workspace tools

nifurtimox 15/20 mg/kg/d 10d + eflornithine 400 mg/kg/d 7d

TERMINATED · PHASE3 · Trypanosomiasis, African

Unknown stopping reason

Registry source

Scientific benefit, asset-specific safety, ownership and licensing: Unknown without reviewed evidence.

Detailed evidence is available in the local Pro plan simulation.